207 related articles for article (PubMed ID: 27476274)
1. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
Francik R; Kryczyk J; Francik S
Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
[TBL] [Abstract][Full Text] [Related]
2. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
[TBL] [Abstract][Full Text] [Related]
3. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Mikhailidis DP; Jagroon IA
Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
[No Abstract] [Full Text] [Related]
4. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Schonfeld G
Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
[TBL] [Abstract][Full Text] [Related]
5. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
[TBL] [Abstract][Full Text] [Related]
6. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Maiguma T; Fujisaki K; Itoh Y; Makino K; Teshima D; Takahashi-Yanaga F; Sasaguri T; Oishi R
Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):289-96. PubMed ID: 12644902
[TBL] [Abstract][Full Text] [Related]
7. [Cytolytic hepatic damage caused by ciprofibrate].
Perault MC; Fievre JL; Dejean C; Martin A; Vandel B
Gastroenterol Clin Biol; 1992; 16(6-7):609. PubMed ID: 1526424
[No Abstract] [Full Text] [Related]
8. Therapeutic effects of fibrates in postprandial lipemia.
Kolovou GD; Kostakou PM; Anagnostopoulou KK; Cokkinos DV
Am J Cardiovasc Drugs; 2008; 8(4):243-55. PubMed ID: 18690758
[TBL] [Abstract][Full Text] [Related]
9. [Fibrates: their prescription must be restricted].
Béliard-Lasserre S
Rev Prat; 2015 Dec; 65(10):1243-4. PubMed ID: 26979011
[No Abstract] [Full Text] [Related]
10. Comparison of effects of fibrates in patients with hypertriglyceridemia.
Suher M; Koç E; Camur B; Sava O
Adv Ther; 2006; 23(5):793-8. PubMed ID: 17142215
[TBL] [Abstract][Full Text] [Related]
11. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
Rizos E; Kostoula A; Elisaf M; Mikhailidis DP
Angiology; 2002; 53(3):273-7. PubMed ID: 12025914
[TBL] [Abstract][Full Text] [Related]
12. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
Raposo HF; Patrício PR; Simões MC; Oliveira HC
J Nutr Biochem; 2014 Jun; 25(6):669-74. PubMed ID: 24746832
[TBL] [Abstract][Full Text] [Related]
13. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
[No Abstract] [Full Text] [Related]
14. Fibrates and renal function.
Gajdos M; Dzúrik R
Clin Nephrol; 2003 Jul; 60(1):65-6. PubMed ID: 12872864
[No Abstract] [Full Text] [Related]
15. A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
Davidson MH
Cardiovasc Drugs Ther; 2009 Oct; 23(5):341-2. PubMed ID: 19844785
[No Abstract] [Full Text] [Related]
16. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
Harvengt C
Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
[No Abstract] [Full Text] [Related]
17. Drug interactions with fibric acids.
Lozada A; Dujovne CA
Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis.
Choi HD; Shin WG
Curr Med Res Opin; 2014 Jan; 30(1):1-10. PubMed ID: 24063624
[TBL] [Abstract][Full Text] [Related]
19. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS
Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Rizzo M; Berneis K
Curr Med Res Opin; 2007 May; 23(5):1103-11. PubMed ID: 17519077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
